135 related articles for article (PubMed ID: 38341669)
1. Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis.
McGonagle D; Kavanaugh A; McInnes IB; Kristensen LE; Merola JF; Strober B; Bolce R; Lisse J; Pustizzi J; Sapin C; Ritchlin C
Rheumatology (Oxford); 2024 Feb; ():. PubMed ID: 38341669
[TBL] [Abstract][Full Text] [Related]
2. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52.
Smolen JS; Mease P; Tahir H; Schulze-Koops H; de la Torre I; Li L; Hojnik M; Sapin C; Okada M; Caporali R; Gratacós J; Goupille P; Liu Leage S; Pillai S; Nash P
Ann Rheum Dis; 2020 Oct; 79(10):1310-1319. PubMed ID: 32660977
[TBL] [Abstract][Full Text] [Related]
3. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.
Mease PJ; Smolen JS; Behrens F; Nash P; Liu Leage S; Li L; Tahir H; Gooderham M; Krishnan E; Liu-Seifert H; Emery P; Pillai SG; Helliwell PS;
Ann Rheum Dis; 2020 Jan; 79(1):123-131. PubMed ID: 31563894
[TBL] [Abstract][Full Text] [Related]
4. Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity.
Armstrong AW; Jaleel T; Merola JF; Gottlieb AB; Khattri S; Helt CC; Malatestinic WN; Ross SE; Ngantcha ME; de Vlam K
Dermatol Ther (Heidelb); 2024 Jun; 14(6):1615-1631. PubMed ID: 38814433
[TBL] [Abstract][Full Text] [Related]
5. Ixekizumab Demonstrates Consistent Efficacy Versus Adalimumab in Biologic Disease-Modifying Anti-rheumatic Drug-Naïve Psoriatic Arthritis Patients Regardless of Psoriasis Severity: 52-Week Post Hoc Results from SPIRIT-H2H.
Kristensen LE; Okada M; Tillett W; Leage SL; El Baou C; Sapin C; Bradley AJ; Meszaros G; Dutz JP; de Vlam K
Rheumatol Ther; 2022 Feb; 9(1):109-125. PubMed ID: 34709605
[TBL] [Abstract][Full Text] [Related]
6. The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2.
Deodhar A; Gladman D; Bolce R; Sandoval D; Park SY; Leage SL; Nash P; Poddubnyy D
Ther Adv Musculoskelet Dis; 2023; 15():1759720X231189005. PubMed ID: 37645684
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis.
Elewski BE; Blauvelt A; Gallo G; Wolf E; McKean-Matthews M; Burge R; Merola JF; Gottlieb AB; Guenther LC
Dermatol Ther (Heidelb); 2022 Apr; 12(4):911-920. PubMed ID: 35279805
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study.
Smolen JS; Sebba A; Ruderman EM; Schulze-Koops H; Sapin C; Gellett AM; Sprabery AT; Li L; de la Torre I; Gallo G; Liu-Leage S; Pillai S; Reis P; Nash P
Rheumatol Ther; 2020 Dec; 7(4):1021-1035. PubMed ID: 33200394
[TBL] [Abstract][Full Text] [Related]
9. A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis.
Kirkham BW; Egeberg A; Behrens F; Pinter A; Merola JF; Holzkämper T; Gallo G; Ng KJ; Bolce R; Schuster C; Nash P; Puig L
Rheumatol Ther; 2023 Oct; 10(5):1127-1146. PubMed ID: 37400681
[TBL] [Abstract][Full Text] [Related]
10. Psoriatic nail involvement and its relationship with distal interphalangeal joint disease.
Lai TL; Pang HT; Cheuk YY; Yip ML
Clin Rheumatol; 2016 Aug; 35(8):2031-2037. PubMed ID: 27251673
[TBL] [Abstract][Full Text] [Related]
11. Ultrasound entheseal abnormalities at the distal interphalangeal joints and clinical nail involvement in patients with psoriasis and psoriatic arthritis, supporting the nail-enthesitis theory.
Acosta-Felquer ML; Ruta S; Rosa J; Marin J; Ferreyra-Garrot L; Galimberti ML; Galimberti R; Garcia-Monaco R; Soriano ER
Semin Arthritis Rheum; 2017 Dec; 47(3):338-342. PubMed ID: 28648658
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Ixekizumab Versus Adalimumab in Biologic-naïve Patients With Active Psoriatic Arthritis and Moderate-to-severe Psoriasis: 52-week Results From the Randomized SPIRIT-H2H Trial.
Reich K; Kristensen LE; Smith SD; Rich P; Sapin C; Leage SL; McKenzie R; Schuster C; Riedl E; Gooderham M
Dermatol Pract Concept; 2022 May; 12(2):e2022104. PubMed ID: 35646453
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of nail disease in psoriatic arthritis by using a modified nail psoriasis severity score index.
Maejima H; Taniguchi T; Watarai A; Katsuoka K
Int J Dermatol; 2010 Aug; 49(8):901-6. PubMed ID: 21174373
[TBL] [Abstract][Full Text] [Related]
14. Multimodal imaging of the distal interphalangeal-joint synovio-entheseal complex in psoriatic arthritis (MIDAS): a cross-sectional study on the diagnostic accuracy of different imaging modalities comparing psoriatic arthritis to psoriasis and osteoarthritis.
Guldberg-Møller J; Mogensen M; Ellegaard K; Zavareh A; Wakefield RJ; Tan AL; Boesen M; Dehmeshki J; Kubassova O; Dreyer L; Henriksen M; Kristensen LE
RMD Open; 2022 Mar; 8(1):. PubMed ID: 35347068
[TBL] [Abstract][Full Text] [Related]
15. Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S).
Wasel N; Thaçi D; French LE; Conrad C; Dutronc Y; Gallo G; Berggren L; Lacour JP
Dermatol Ther (Heidelb); 2020 Aug; 10(4):663-670. PubMed ID: 32415575
[TBL] [Abstract][Full Text] [Related]
16. Histological Evaluation of the Relationships Between Distal Interphalangeal Psoriatic Arthritis and Nail Psoriasis: Correlations With Anatomical Studies of the Normal Nail Unit and the Main Radiological Data Concerning Distal Interphalangeal Psoriatic Arthritis.
Perrin C
Am J Dermatopathol; 2020 Dec; 42(12):911-915. PubMed ID: 32889808
[TBL] [Abstract][Full Text] [Related]
17. Psoriatic Nail Dystrophy Is Associated with Erosive Disease in the Distal Interphalangeal Joints in Psoriatic Arthritis: A Retrospective Cohort Study.
Antony AS; Allard A; Rambojun A; Lovell CR; Shaddick G; Robinson G; Jadon DR; Holland R; Cavill C; Korendowych E; McHugh NJ; Tillett W
J Rheumatol; 2019 Sep; 46(9):1097-1102. PubMed ID: 30824637
[TBL] [Abstract][Full Text] [Related]
18. Is the involvement of the distal interphalangeal joint in psoriatic patients related to nail psoriasis?
Scarpa R; Manguso F; Oriente A; Peluso R; Atteno M; Oriente P
Clin Rheumatol; 2004 Feb; 23(1):27-30. PubMed ID: 14749978
[TBL] [Abstract][Full Text] [Related]
19. Psoriatic Nail Changes Are Associated With Clinical Outcomes in Psoriatic Arthritis.
Sandre MK; Rohekar S; Guenther L
J Cutan Med Surg; 2015; 19(4):367-76. PubMed ID: 25775610
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1).
van der Heijde D; Gladman DD; Kishimoto M; Okada M; Rathmann SS; Moriarty SR; Shuler CL; Carlier H; Benichou O; Mease PJ
J Rheumatol; 2018 Mar; 45(3):367-377. PubMed ID: 29247148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
